Atorvastatin
- Generic Name
- Atorvastatin
- Brand Names
- Atorvaliq, Caduet, Lipitor, Lypqozet
- Drug Type
- Small Molecule
- Chemical Formula
- C33H35FN2O5
- CAS Number
- 134523-00-5
- Unique Ingredient Identifier
- A0JWA85V8F
- Background
Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylg...
- Indication
Atorvastatin is indicated for the treatment of several types of dyslipidemias, including primary hyperlipidemia and mixed dyslipidemia in adults, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.
...
- Associated Conditions
- Anginal Pain, Cardiovascular Complications, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Coronary artery thrombosis, Dysbetalipoproteinemia, Fredrickson Type III lipidemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hospitalizations, Hypertension, Essential Hypertension, Hypertriglyceridemias, Mixed Dyslipidemias, Mixed Hyperlipidemia, Myocardial Infarction, Non-familial hypercholesterolemia, Nonfatal Myocardial Infarction, Postoperative Thromboembolism, Primary Hypercholesterolemia, Stroke, Thrombosis, Transient Ischemic Attack, Elevation of serum triglyceride levels, Heterozygous familial hyperlipidemia, Non-familial hyperlipidemia, Primary Hyperlipidemia, Revascularization procedures
- Associated Therapies
- -
Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis
- First Posted Date
- 2004-10-15
- Last Posted Date
- 2017-04-28
- Target Recruit Count
- 82
- Registration Number
- NCT00094172
- Locations
- 🇺🇸
Yale MS Research Center, New Haven, Connecticut, United States
🇨🇦Montreal Neurological Institute, Montreal, Quebec, Canada
🇺🇸Mount Sinai School of Medicine, New York, New York, United States
Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL
- Conditions
- First Posted Date
- 2004-03-12
- Last Posted Date
- 2006-11-01
- Lead Sponsor
- Kos Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT00079638
Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)
- Conditions
- Interventions
- First Posted Date
- 2003-08-04
- Last Posted Date
- 2013-08-15
- Lead Sponsor
- Laura Schanberg
- Target Recruit Count
- 221
- Registration Number
- NCT00065806
- Locations
- 🇺🇸
Duke Medical Center / Duke Clinical Research Institute, Durham, North Carolina, United States
Pediatric Kidney Transplant Without Calcineurin Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2016-10-21
- Target Recruit Count
- 35
- Registration Number
- NCT00023231
- Locations
- 🇺🇸
Lauren Schenker, Rockville, Maryland, United States
The Inhibition of Platelet Antiaggregating Activity of Clopidogrel by Atorvastatin Detected by Erythromycin Breath Test: a Metabolic Inhibition of Hepatic Cytochrome P450-3A
- Conditions
- First Posted Date
- 2000-02-14
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Registration Number
- NCT00004564
- Locations
- 🇺🇸
1G323 University Hospital, Box 0048 1500 E Medical Center Drive, Ann Arbor, Michigan, United States
Pilot Study of Atorvastatin in Children With Chronic Hyperlipidemia Secondary to Nephrotic Syndrome
- Conditions
- Interventions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2017-09-15
- Target Recruit Count
- 5
- Registration Number
- NCT00004466
- Locations
- 🇺🇸
Medical City Dallas Hospital, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.